These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 38180225)
21. Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfunction. Fortin JS; Benskey MJ; Lookingland KJ; Patterson JS; Howey EB; Goudreau JL; Schott HC BMC Vet Res; 2020 Sep; 16(1):356. PubMed ID: 32977825 [TBL] [Abstract][Full Text] [Related]
22. Comparison of hair follicle histology between horses with pituitary pars intermedia dysfunction and excessive hair growth and normal aged horses. InnerĂ¥ M; Petersen AD; Desjardins DR; Steficek BA; Rosser EJ; Schott HC Vet Dermatol; 2013 Feb; 24(1):212-7.e46-7. PubMed ID: 23331700 [TBL] [Abstract][Full Text] [Related]
23. Computed tomographic findings in the pituitary gland and brain of horses with pituitary pars intermedia dysfunction. Pease AP; Schott HC; Howey EB; Patterson JS J Vet Intern Med; 2011; 25(5):1144-51. PubMed ID: 21985144 [TBL] [Abstract][Full Text] [Related]
24. Descriptive analysis of horses and ponies attending horse auctions in Victoria from July 2019 to March 2020. Chapman GR; Wells B; Gilkerson JR; Flash ML Aust Vet J; 2023 Jan; 101(1-2):1-8. PubMed ID: 36176071 [TBL] [Abstract][Full Text] [Related]
25. Effects of pituitary pars intermedia dysfunction and Prascend (pergolide tablets) treatment on endocrine and immune function in horses. Miller AB; Loynachan AT; Bush HM; Hart KA; Barker VD; Campana-Emard AG; Grubbs ST; Adams AA Domest Anim Endocrinol; 2021 Jan; 74():106531. PubMed ID: 32942194 [TBL] [Abstract][Full Text] [Related]
26. Assessment of tissue-specific cortisol activity with regard to degeneration of the suspensory ligaments in horses with pituitary pars intermedia dysfunction. Hofberger SC; Gauff F; Thaller D; Morgan R; Keen JA; Licka TF Am J Vet Res; 2018 Feb; 79(2):199-210. PubMed ID: 29359976 [TBL] [Abstract][Full Text] [Related]
27. Neutrophil function in healthy aged horses and horses with pituitary dysfunction. McFarlane D; Hill K; Anton J Vet Immunol Immunopathol; 2015 Jun; 165(3-4):99-106. PubMed ID: 25962580 [TBL] [Abstract][Full Text] [Related]
28. Pituitary pars intermedia dysfunction does not necessarily impair insulin sensitivity in old horses. Mastro LM; Adams AA; Urschel KL Domest Anim Endocrinol; 2015 Jan; 50():14-25. PubMed ID: 25240230 [TBL] [Abstract][Full Text] [Related]
29. Nitration and increased alpha-synuclein expression associated with dopaminergic neurodegeneration in equine pituitary pars intermedia dysfunction. McFarlane D; Dybdal N; Donaldson MT; Miller L; Cribb AE J Neuroendocrinol; 2005 Feb; 17(2):73-80. PubMed ID: 15796757 [TBL] [Abstract][Full Text] [Related]
30. The effect of freeze-thaw cycles on determination of immunoreactive plasma adrenocorticotrophic hormone concentrations in horses. Hu K; Stewart AJ; Yuen KY; Hinrichsen S; Dryburgh EL; Bertin FR J Vet Intern Med; 2020 May; 34(3):1350-1356. PubMed ID: 32255541 [TBL] [Abstract][Full Text] [Related]
31. Prevalence, risk factors and clinical signs predictive for equine pituitary pars intermedia dysfunction in aged horses. McGowan TW; Pinchbeck GP; McGowan CM Equine Vet J; 2013 Jan; 45(1):74-9. PubMed ID: 22594955 [TBL] [Abstract][Full Text] [Related]
32. BEVA primary care clinical guidelines: Diagnosis and management of equine pituitary pars intermedia dysfunction. Menzies-Gow NJ; Banse HE; Duff A; Hart N; Ireland JL; Knowles EJ; McFarlane D; Rendle D Equine Vet J; 2024 Mar; 56(2):220-242. PubMed ID: 37795557 [TBL] [Abstract][Full Text] [Related]
33. Effects of advanced age and pituitary pars intermedia dysfunction on components of the acute phase reaction in horses. Zak A; Siwinska N; Elzinga S; Barker VD; Stefaniak T; Schanbacher BJ; Place NJ; Niedzwiedz A; Adams AA Domest Anim Endocrinol; 2020 Jul; 72():106476. PubMed ID: 32380311 [TBL] [Abstract][Full Text] [Related]
34. Markers of muscle atrophy and impact of treatment with pergolide in horses with pituitary pars intermedia dysfunction and muscle atrophy. Banse HE; Whitehead AE; McFarlane D; Chelikani PK Domest Anim Endocrinol; 2021 Jul; 76():106620. PubMed ID: 33740552 [TBL] [Abstract][Full Text] [Related]
35. Lamellar pathology in horses with pituitary pars intermedia dysfunction. Karikoski NP; Patterson-Kane JC; Singer ER; McFarlane D; McGowan CM Equine Vet J; 2016 Jul; 48(4):472-8. PubMed ID: 25869529 [TBL] [Abstract][Full Text] [Related]
36. Impact of blue light therapy on plasma adrenocorticotropic hormone (ACTH) and hypertrichosis in horses with pituitary pars intermedia dysfunction. Miller AB; Murphy BA; Adams AA Domest Anim Endocrinol; 2022 Jan; 78():106651. PubMed ID: 34656964 [TBL] [Abstract][Full Text] [Related]
37. Age-related Qualitative Histological and Quantitative Stereological Changes in the Equine Pituitary. Leitenbacher J; Herbach N J Comp Pathol; 2016; 154(2-3):215-24. PubMed ID: 26810844 [TBL] [Abstract][Full Text] [Related]
38. Severe hypertriglyceridaemia in horses and ponies with endocrine disorders. Dunkel B; Wilford SA; Parkinson NJ; Ward C; Smith P; Grahame L; Brazil T; Schott HC Equine Vet J; 2014 Jan; 46(1):118-22. PubMed ID: 23663085 [TBL] [Abstract][Full Text] [Related]
39. Diagnosis of equine endocrinopathies: The value of measuring blood glucose during an oral glucose test. de Laat MA; Sillence MN Vet J; 2023; 300-302():106034. PubMed ID: 37778651 [TBL] [Abstract][Full Text] [Related]
40. Incidence of laminitis and survey of dietary and management practices in pleasure horses and ponies in south-eastern Australia. Potter SJ; Bamford NJ; Harris PA; Bailey SR Aust Vet J; 2017 Oct; 95(10):370-374. PubMed ID: 28948628 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]